Sign In
Buy CMMB
$1.72
-0.0200 (-1.15%)
At Close: Jun 03, 2026
Chemomab Therapeutics stock soars after FDA clears IND for SSc treatment
08:25am, Tuesday, 21'st Feb 2023
Shares of Chemomab Therapeutics Ltd. CMMB, -0.51% shot up 46.9% in premarket trading Tuesday, after the Israel-based biotechnology company said the U.S. Food and Drug Administration cleared its Invest
Chemomab Therapeutics Ltd. (CMMB) Q3 2022 Earnings Call Transcript
12:00pm, Friday, 11'th Nov 2022
Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Da
Chemomab Therapeutics to Present at Upcoming Scientific Conferences
07:00am, Friday, 28'th Oct 2022
TEL AVIV, Israel , Oct. 28, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative th
Chemomab Therapeutics Ltd. (CMMB) CEO Dale Pfost on Q2 2022 Results - Earnings Call Transcript
02:40pm, Friday, 12'th Aug 2022
Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q2 2022 Earnings Conference Call August 12, 2022 8:00 AM ET CompanyParticipants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale
Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update
07:00am, Monday, 01'st Aug 2022
TEL AVIV, Israel , Aug. 1, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative the
Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment Conference
07:00am, Wednesday, 18'th May 2022
TEL AVIV, Israel , May 18, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative th
Chemomab Therapeutics Ltd. (CMMB) CEO Dale Pfost on Q1 2022 Results - Earnings Call Transcript
05:43pm, Thursday, 12'th May 2022
Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pf
New Strong Sell Stocks for March 14th
08:17am, Monday, 14'th Mar 2022
AVYA, BGS, and CMMB have been added to the Zacks Rank #5 (Strong Sell) List on March 14, 2022.
Chemomab Therapeutics Ltd (CMMB) CEO Dale Pfost on Q4 2021 Results - Earnings Call Transcript
10:48am, Wednesday, 09'th Mar 2022
Chemomab Therapeutics Ltd (CMMB) CEO Dale Pfost on Q4 2021 Results - Earnings Call Transcript
Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer
07:00am, Thursday, 02'nd Sep 2021
TEL AVIV, Israel, Sept. 2, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd.
Chemomab to Participate in Upcoming September Investor Conferences
07:18am, Wednesday, 01'st Sep 2021
TEL AVIV, Israel, Sept. 1, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd.
Chemomab Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update
08:00am, Friday, 13'th Aug 2021
TEL AVIV, Israel, Aug. 13, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fib
Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III
08:30am, Wednesday, 23'rd Jun 2021
TEL AVIV, Israel and SEATTLE, June 23, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therape
CMMB Stock Price: Over 4% Increase Pre-Market Details
04:40am, Monday, 14'th Jun 2021
The stock price of Chemomab Therapeutics Ltd (NASDAQ: CMMB) increased by over 4% pre-market. These are the details.
Chemomab Therapeutics Is Heating Up And Could See A Move Soon
12:27pm, Friday, 11'th Jun 2021
Chemomab Therapeutics LTD. (NASDAQ: CMMB) shares are trading higher Friday as retail traders continue to push stocks higher.
